In the training, validation, and test sets, the model predicted high PD-L1 expression (>50%) with AUC values of 0.78, 0.71, and 0.76, respectively, aiding in identifying NSCLC populations likely to benefit from immunotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.